RxDoctor Payments Data

Jasrai Gill, MD

Cardiovascular Disease · Toms River, NJNPI 1538336904

Payments from drug & device makers

$24,837in general payments, 2019–2025

Across 1,249 payments — averaging $19.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$5K
  • Medtronic$3K
  • Novartis$2K
  • Boston Scientific$2K
  • E.r. Squibb & Sons, L.L.C.$1K
  • AstraZeneca$1K
  • plus $11K from 48 others

What the payments were for

  • Travel & lodging$7223%
  • Food & beverage$24,00897%
  • Education$1070%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,837 in reported general payments places this provider in the 85th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$1,036,432
Medicare patients
1,460
Services billed
7,921

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban537$751,602
EntrestoSacubitril/Valsartan173$259,962
XareltoRivaroxaban121$151,521
FarxigaDapagliflozin Propanediol66$85,171
Repatha SureclickEvolocumab102$84,490
BrilintaTicagrelor82$78,775
WegovySemaglutide43$68,297
JardianceEmpagliflozin52$58,478
VascepaIcosapent Ethyl41$25,589
MounjaroTirzepatide16$22,700
OzempicSemaglutide17$22,294
Repatha SyringeEvolocumab15$14,183
Icosapent Ethyl46$13,840
Atorvastatin Calcium850$12,084
Metoprolol Succinate575$10,706

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$595$751,602537 claims
NovartisEntresto$1,915$259,962173 claims
AstraZenecaFarxiga, Brilinta$1,440$163,946148 claims
Johnson & JohnsonXarelto$1,129$151,521121 claims
Novo NordiskWegovy, Ozempic$324$90,59160 claims
Boehringer IngelheimJardiance$621$58,47852 claims
Lilly USA, LLCMounjaro$20$22,70016 claims
Kowa Pharmaceuticals America, Inc.Livalo$166$7,32713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Toms River

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →